NuPathe, a US-based drug developer focused on the central nervous system, is preparing to list five million shares at between $14 and $16 each with an initial market capitalisation of $225m.

BioTechCube (BTC), a newly-formed Luxembourg-based investment company backed by the state, replaced dievini Hopp BioTech as $10m is drawn down from Integrated Diagnostics' $30m series A round.

Euthymics Bioscience, a US-based developer of antidepressants, raises $24m from Novartis and venture capital firms to acquire DOV and develop drugs.

Venture consortium continues to support Cara Therapeutics in its series D round after more than $55m in five year.

US regulatory filing shows Sorbent Therapeutics gains nearly maximum round to treat renal problems.

Venture backing to biotech company Pacific Biosciences takes funding to $370m.

Norwest Venture Partners joins venture peers in backing India-based Perfint Healthcare.

Former head of strategy and operations for strategic alliances at Switzerland-based drugs company Novartis' Institutes for BioMedical Research joins venture-backed Vitae Pharmaceuticals.

Series D round for US medical devices company Ventus Medical boosts funding for Stanford lecturer.

Denmark-based Novo, which has as one of the largest and most influential corporate venturing units by Global Corporate Venturing in June, is one of two co-leaders in diabetes company Reata's $78m investment round.